Medicare And Alzheimer’s Drugs: Recent NCDs Mainly Omit Research Requirement, Biogen Notes

Most of the Medicare national coverage determinations for drugs issued by the Centers for Medicare and Medicaid Services over the past 20 years did not condition reimbursement on further evidence development, Biogen, Inc. US president Alisha Alaimo pointed out.

That could suggest that CMS will not require further evidence generation for Biogen’s recently-approved drug for Alzheimer’s disease Aduhelm, or other amyloid-directed monoclonal